<DOC>
	<DOCNO>NCT02563002</DOCNO>
	<brief_summary>In study , participant MSI-H dMMR advance colorectal carcinoma randomly assign receive either pembrolizumab Investigator 's choice 1 6 standard care ( SOC ) chemotherapy regimens treatment advanced colorectal carcinoma . The primary study hypothesis pembrolizumab prolong progression-free survival ( PFS ) compare current SOC chemotherapy .</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) v Standard Therapy Participants With Microsatellite Instability-High ( MSI-H ) Mismatch Repair Deficient ( dMMR ) Stage IV Colorectal Carcinoma ( MK-3475-177/KEYNOTE-177 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Microsatellite Instability</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Locally confirm dMMR MSIH stage IV colorectal carcinoma Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy least 3 month Measurable disease Female participant childbearing potential must willing use adequate contraception course study start first dose study medication 180 day last dose SOC therapy 120 day last pembrolizumab dose Male participant must agree use adequate contraception course study start first dose study medication 180 day last dose SOC therapy 120 day last pembrolizumab dose Adequate organ function Has receive prior systemic therapy Stage IV colorectal cancer . May receive prior adjuvant chemotherapy colorectal cancer long complete least 6 month prior randomization study Currently participate receive treatment another study , participate study investigational agent receive treatment , use investigational device within 4 week randomization Active autoimmune disease require systemic treatment past 2 year Diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior randomization study Radiation therapy within 4 week prior randomization study recover baseline adverse event due radiation therapy Known active central nervous system ( CNS ) metastases and/or carcinomatous meningitis Major surgical procedure , open biopsy significant traumatic injury within 28 day prior randomization study Has receive prior therapy immune checkpoint inhibitor ( e.g. , antiprogrammed cell death [ PD ] 1 , antiPD ligand 1 [ L1 ] , antiPDL2 agent , anticytotoxic Tlymphocyteassociated protein 4 [ CTLA4 ] agent , etc . ) Another malignancy progress require active treatment exception nonmelanomatous skin cancer undergone potentially curative therapy situ cervical carcinoma Received live vaccine within 30 day plan start study medication Known history Human Immunodeficiency Virus ( HIV ) , Hepatitis B C Known history , evidence interstitial lung disease active , noninfectious pneumonitis Active infection require systemic therapy Known psychiatric substance abuse disorder would interfere cooperation requirement study Pregnant , breastfeeding , expect conceive father child within project duration study , start screen visit 180 day last dose SOC 120 day last dose pembrolizumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>